Standardized implementation of minimally invasive surgery for Siewert Ⅱ esophagogastric junction adenocarcinoma.
10.3760/cma.j.cn441530-20211221-00521
- Author:
Jia Ming ZHU
1
;
Xin WANG
1
;
Zi Ming GAO
1
;
Zhen Ning WANG
1
Author Information
1. Department of Gastrointestinal Oncology Surgery, The First Affiliated Hospital of China Medical University, Shenyang 110001, China.
- Publication Type:Journal Article
- Keywords:
Adenocarcinoma of the esophagogastric junction;
Research progress;
Siewert type II;
Surgery
- MeSH:
Adenocarcinoma/pathology*;
Esophageal Neoplasms/surgery*;
Esophagogastric Junction/surgery*;
Gastrectomy;
Humans;
Lymph Node Excision;
Minimally Invasive Surgical Procedures;
Prospective Studies;
Retrospective Studies;
Stomach Neoplasms/pathology*
- From:
Chinese Journal of Gastrointestinal Surgery
2022;25(2):104-108
- CountryChina
- Language:Chinese
-
Abstract:
The incidence of Siewert type II adenocarcinoma of the esophagogastric junction (AEG) is increasing year by year. Due to its special anatomical location and biological behavior, the treatment of AEG is still controversial in terms of lymph node dissection, the esophageal resection margin, range of gastrectomy, and the choice of reconstruction modality for postoperative gastrointestinal tract. The advent of the minimally invasive era has brought the treatment of Siewert type II AEG to a stage of gradual improvement and standardization. Experts of China are also actively exploring the value of minimally invasive surgery in the treatment of AEG through multicenter trials (CLASS-10, etc.). It is believed that based on the active development of many clinical studies, basic experimental studies and large prospective clinical studies, the strengthening of communication and cooperation among various disciplines and the innovative application of new technologies can bring greater survival benefits to patients.
